Comparison

Ginsenoside Ro European Partner

Item no. TMO-T3915-25mg
Manufacturer TargetMol
CASRN 34367-04-9
Amount 25 mg
Quantity options 100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mg 1 mL 200 mg 25 mg 2 mg 500 mg 50 mg 5 mg
Category
Type Molecules
Specific against other
Purity 0,9966
Citations 1. Kang HJ, et al. Antioxidative properties of ginsenoside Ro against UV-B-induced oxidative stress in human dermal fibroblasts. Biosci Biotechnol Biochem. 2015 Jul 27:1-4.
Smiles CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias Chikusetsusaponin 5,Polysciasaponin P3,Chikusetsusaponin V
Shipping Condition Cool pack
Available
Manufacturer - Targets
Prostaglandin Receptor|||Reductase|||Calcium Channel
Shipping Temperature
Cool pack
Storage Conditions
-20
Molecular Weight
957.11
Description
Ginsenoside Ro (Chikusetsusaponin V) can reduce TXA2 production, weakly reduce COX-1 and TXAS activities, and has antiplatelet effects as a Ca2+ antagonist with an IC50 of 155 μM.
Pathways
Immunology/Inflammation|||GPCR/G Protein|||Endocrinology/Hormones|||Metabolism|||Membrane transporter/Ion channel

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close